Phase
Condition
Pancreatic Cancer
Digestive System Neoplasms
Pancreatitis
Treatment
Vitmain C plus herbal medicine
Clinical Study ID
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
• Ability to understand and the willingness to sign a written informed consentdocument.
Age ≥ 18 years and ≤ 80 years.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.
Adequate organ performance based on laboratory blood tests.
Presence of at least of one measurable lesion in agreement to RECIST criteria.
Hemoglobin (Hgb) ≥ 8 g/dL.
The expected survival ≥ 3 months.
Women of childbearing potential and men must agree to use adequatecontraception prior to study entry and for the duration of study participation.
Exclusion
Exclusion Criteria:
• Patients who have received anti-tumor treatment for other types of cancer in thelast two years.
Patients who have received any form of anti-tumor therapy for pancreaticcancer.
The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.
Inflammation of the digestive tract, including pancreatitis, cholecystitis,cholangitis, etc.
Pregnant or nursing women.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Severe and uncontrollable accompanying diseases that may affect protocolcompliance or interfere with the interpretation of results, including activeopportunistic infections or advanced (severe) infections, and diabetes thatcannot be controlled after adequate clinical anti-hyperglycemia treatmentaccording to guidelines, uncontrollable hypertension, cardiovascular disease (Class III or IV heart failure as defined by the New York Heart Associationclassification, congestive heart failure (CHF), myocardial infarction in thepast 6 months , unstable arrhythmia or unstable angina, cerebral infarctionwithin 3 months, etc).
Renal insufficiency or dialysis
History of allergic reactions attributed to compounds of similar chemical orbiologic composition to gemcitabine, nab-paclitaxel, or other agents used inthe study.
Other serious accompanying illnesses, which, in the researcher's opinion,could seriously adversely affect the safety of the treatment.
Patients who are unwilling or unable to comply with study procedures.
Study Design
Study Description
Connect with a study center
Shanghai Cancer Center
Shanghai, 200032
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.